Dolutegravir, Emtricitabine and Tenofovir alafenamide 50 mg/200 mg/25 mg is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 40 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).